A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effects of VX-702 in subjects with
moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.